Aqua Pharmaceuticals, LLC Announces Launch of Cordran® Ointment (flurandrenolide ointment, USP) 0.05%
WEST CHESTER, Pa.--(BUSINESS WIRE)--West Chester-based Aqua Pharmaceuticals, an Almirall company, today announces the launch of Cordran® Ointment (flurandrenolide ointment, USP) 0.05%. Cordran® Ointment is a Class 4 topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
“For quite some time, physicians have relied on Cordran® Lotion and Cordran® Cream to help treat a variety of skin conditions. With the launch of Cordran® Ointment, physicians will have another tool in the bag to provide the best quality care for their patients.”
“Cordran® is a name well-known throughout the dermatology community,” said Ted White, Chief Operating Officer at Aqua. “For quite some time, physicians have relied on Cordran® Lotion and Cordran® Cream to help treat a variety of skin conditions. With the launch of Cordran® Ointment, physicians will have another tool in the bag to provide the best quality care for their patients.”
Cordran® Ointment is preservative-free and does not contain propylene glycol. Because of its ointment formulation, Cordran® Ointment may be particularly helpful for patients with very dry skin. It is supplied in 60 gram aluminum tubes.
Important Safety Information Regarding Cordran® Lotion, Cream and Ointment 0.05%
- Systemic absorption of topical corticosteroids has produced reversible HPA axis suppression, Cushing’s syndrome, hyperglycemia, and glucosuria.
- Increased absorption may occur with the use of more potent steroids, use over large surface areas or with occlusive dressings, prolonged use, or use in pediatric patients.
- Patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression using urine free cortisol and ACTH stimulation tests.
- Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than do adults because of a larger skin surface area to body weight ratio.
- Local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings.
- The most common adverse events with Cordran® were burning, itching, irritation, and dryness.
- The following adverse reactions have been identified during post-approval use of Cordran®: hypersensitivity, contact dermatitis, skin discoloration, skin striae and skin atrophy.
About Aqua Pharmaceuticals
Headquartered in West Chester, Pennsylvania, Aqua Pharmaceuticals, an Almirall company, is dedicated to helping patients achieve their goals of healthy skin and a positive self-image. The company has leading branded prescription drugs in four therapeutic categories that include acne, steroid-responsive dermatoses, actinic keratoses and seborrheic dermatitis. For more information, visit www.aquapharm.com.